ASAS PRESS

Scientific Challenges of Anti-Aging Technology

2 min read0.0(0)82 views
التحديات العلمية للتقنية المضادة للaging
E

By

Editorial Team

The News

Russian President Vladimir Putin and Chinese President Xi Jinping discussed the possibility of realizing the ancient aspiration of immortality through advances in medicine and technological biology during their joint talks. The Russian side indicated that billions of dollars are being directed toward organ transplant research and regenerative medicine, while the Chinese president expressed cautious optimism based on expectations that humans may live up to 150 years this century.

The field of technological biology of aging is defined as an approach that uses biological systems themselves to address mechanisms of age-related diseases, with the goal of increasing healthspan or total lifespan for individuals. This field witnessed a massive investment surge in the first quarter of 2026, where its companies raised approximately $3.74 billion, driven by the success of obesity drugs which became top global sellers and reshaped the medical landscape.

Researchers are currently basing their work on understanding the twelve processes of aging at the molecular and cellular levels, which include factors such as genomic instability and chronic inflammation. This understanding has enabled the development of treatments in animal models that have altered health metrics and extended lifespan. However, the field faces significant theoretical and practical challenges; notably, the U.S. Food and Drug Administration (FDA) does not currently consider aging itself a disease target, which requires companies to prove benefits against specific diseases or measurable health aspects rather than extending lifespan directly.

Furthermore, the nature of aging as an intrinsic biological reality in all living organisms makes attempts to treat it potentially carry significant unknown side effects so far. Scientists need years, and perhaps decades, to demonstrate the effectiveness of these treatments in meaningfully extending healthspan or lifespan, especially since some research branches attempt to manipulate DNA replication processes that are still under study.

Analysis & Context

From an analytical perspective, the shift in investments toward "longevity" companies represents a fundamental transformation in modern medical philosophy, where the goal is no longer merely treating symptoms but addressing the root biological causes of aging. Modern obesity drugs serve as an early example of this success, having demonstrated high effectiveness in a financially booming market, thereby boosting investor confidence in their ability to solve more complex biological puzzles such as aging itself.

In the broader context, these technologies face major theoretical and practical challenges, foremost among them being that the U.S. Food and Drug Administration does not classify aging as a disease per se. This forces companies to prove the efficacy of their treatments against specific diseases or measurable health indicators instead of extending lifespan as a direct objective. Additionally, the intrinsic nature of aging as a biological reality in all living organisms means that any attempt to manipulate it is susceptible to unknown side effects, and it may take years or even decades before confirming whether these treatments are viable for meaningfully extending human healthspan or lifespan.

Source: Al Jazeera

Share this article:

Follow ASAS PRESS

Daily news and analysis, right in your feed on your favorite platform.

Related Articles

Comments (0)

Leave a comment